U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C27H26N4O4S
Molecular Weight 502.585
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EFATUTAZONE

SMILES

CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC4=CC=C(OC5=CC(C)=C(N)C(C)=C5)C=C14

InChI

InChIKey=JCYNMRJCUYVDBC-UHFFFAOYSA-N
InChI=1S/C27H26N4O4S/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33)

HIDE SMILES / InChI

Molecular Formula C27H26N4O4S
Molecular Weight 502.585
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Efatutazone (CS-7017 or RS-5444) is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with antineoplastic properties. Mediated through activation of PPAR-gamma, this agent is capable of inducing cell differentiation and apoptosis, thereby leading to a reduction in cellular proliferation. Efatutazone was in clinical trials for the treatment of solid tumors however; its development has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P37231|||Q15179
Gene ID: 5468.0
Gene Symbol: PPARG
Target Organism: Homo sapiens (Human)
Target ID: P37231|||Q15179
Gene ID: 5468.0
Gene Symbol: PPARG
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Phase I trial: 0.10 to 1.15 mg PO twice daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:35:43 GMT 2023
Edited
by admin
on Sat Dec 16 16:35:43 GMT 2023
Record UNII
M17ILL71MC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EFATUTAZONE
INN   WHO-DD  
INN  
Official Name English
INOLITAZONE
Common Name English
efatutazone [INN]
Common Name English
Efatutazone [WHO-DD]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-((6-(4-AMINO-3,5-DIMETHYLPHENOXY)-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-
Systematic Name English
RAC-5-((4-((6-(4-AMINO-3,5-DIMETHYLPHENOXY)-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-1,3-THIAZOLIDINE-2,4-DIONE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1934
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
Code System Code Type Description
FDA UNII
M17ILL71MC
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
DRUG BANK
DB11894
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
EVMPD
SUB123154
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID60944956
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
SMS_ID
100000145199
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
CAS
223132-37-4
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
INN
9040
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
PUBCHEM
9832447
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
NCI_THESAURUS
C83819
Created by admin on Sat Dec 16 16:35:44 GMT 2023 , Edited by admin on Sat Dec 16 16:35:44 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY